Mean change in BMD of the femoral neck · postmenopausal women with osteoporosis and CKD stages 5 and 5D
It is very uncertain whether raloxifene changes mean change in BMD of the femoral neck compared with placebo (very low certainty).
1 finding from 1 review
Mean change in BMD of the lumbar spine · postmenopausal women with osteoporosis and CKD stages 5 and 5D
Raloxifene may leads to higher mean change in BMD of the lumbar spine compared with placebo (low certainty).
1 finding from 1 review
Total hip BMD · postmenopausal women with osteoporosis and CKD stages 5 and 5D
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Mean change in BMD of the distal radius · postmenopausal women with osteoporosis and CKD stages 5 and 5D
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · postmenopausal women with osteoporosis and CKD stages 5 and 5D
1 finding from 1 review
Death · postmenopausal women with osteoporosis and CKD stages 5 and 5D
It is very uncertain whether raloxifene changes death compared with placebo (very low certainty).
1 finding from 1 review
QoL · postmenopausal women with osteoporosis and CKD stages 5 and 5D
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Clinical fracture · postmenopausal women with osteoporosis and CKD stages 3‐4
Any anti‐osteoporotic drugs showed no clear difference in clinical fracture compared with placebo (moderate certainty).
1 finding from 1 review
Mean change in BMD of the femoral neck · postmenopausal women with osteoporosis and CKD stages 3‐4
1 finding from 1 review
Mean change in BMD of the lumbar spine · postmenopausal women with osteoporosis and CKD stages 3‐4
1 finding from 1 review
Total hip BMD · postmenopausal women with osteoporosis and CKD stages 3‐4
1 finding from 1 review
Mean change in BMD of the distal radius · postmenopausal women with osteoporosis and CKD stages 3‐4
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · postmenopausal women with osteoporosis and CKD stages 3‐4
Any anti‐osteoporotic drugs showed no clear difference in adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Death · postmenopausal women with osteoporosis and CKD stages 3‐4
1 finding from 1 review
QoL · postmenopausal women with osteoporosis and CKD stages 3‐4
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Improvement in disability grade after 4 weeks · patients with Guillain‐Barré syndrome
1 finding from 1 review
Time from randomisation until recovery of unaided walking · patients with Guillain‐Barré syndrome
1 finding from 1 review
Time from randomisation until discontinuation of ventilation (for those ventilated) · patients with Guillain‐Barré syndrome
1 finding from 1 review
no estimate extracted
1 study · 5 participants
Very low
Death · patients with Guillain‐Barré syndrome
It is very uncertain whether brain‐derived neurotrophic factor changes death compared with placebo (very low certainty).
1 finding from 1 review
Death or disability after 12 months · patients with Guillain‐Barré syndrome
It is very uncertain whether brain‐derived neurotrophic factor changes death or disability after 12 months compared with placebo (very low certainty).
1 finding from 1 review